title: Effect of thymoglobulin induction on HIV-infected renal transplant recipients: differences between HIV-positive and HIV-negative patients.
abstract: The best immunosuppressive regimen in HIV-infected renal transplant recipients has not been established. Thymoglobulin has been associated with an increased risk of serious bacterial infections in HIV-negative patients and, for this reason, there is some concern over its use in the HIV-infected population. We describe three consecutive HIV-infected renal transplant recipients who received thymoglobulin as induction therapy, and we compared their progress with a cohort of 23 HIV-negative recipients. Median follow-up was 24 and 11 months, respectively. Nadir lymphocytopenia was observed at 1 week in both groups, and their absolute lymphocyte count recovery was similar. An early and deep (<30 cells/mm(3)) CD4(+) T cell lymphocytopenia was seen in two of the three HIV-infected patients. No opportunistic infections were diagnosed in HIV-positive patients. One HIV-positive patient had a bacterial infection and five HIV-negative patients had one or more bacterial infections. Thymoglobulin was safe in our three HIV-infected renal transplant recipients. Until those data are confirmed in larger studies, close monitoring is recommended during the thymoglobulin-induced CD4(+) T cell lymphocytopenia period.
authors.affiliation: Infectious Diseases Service, University of Barcelona, Barcelona, Spain.
authors.forename: Joan C
authors.initials: JC
authors.lastname: Trullas
authors.forename: Frederic
authors.initials: F
authors.lastname: Cofan
authors.forename: Stefania
authors.initials: S
authors.lastname: Cocchi
authors.forename: Carlos
authors.initials: C
authors.lastname: Cervera
authors.forename: Laura
authors.initials: L
authors.lastname: Linares
authors.forename: Fernando
authors.initials: F
authors.lastname: Aguero
authors.forename: Frederic
authors.initials: F
authors.lastname: Oppenheimer
authors.forename: Asuncion
authors.initials: A
authors.lastname: Moreno
authors.forename: Jose M
authors.initials: JM
authors.lastname: Campistol
authors.forename: Jose M
authors.initials: JM
authors.lastname: Miró
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000961:Antilymphocyte Serum; D023241:Antiretroviral Therapy, Highly Active; D001424:Bacterial Infections; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000150:complications / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; C512542:thymoglobulin